Comparative Pharmacology
Head-to-head clinical analysis: FACTIVE versus MOXEZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FACTIVE versus MOXEZA.
FACTIVE vs MOXEZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gemifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination.
400 mg orally once daily for 5 days for acute exacerbation of chronic bronchitis; 400 mg orally once daily for 7 days for community-acquired pneumonia; 400 mg orally once daily for 5 days for acute bacterial sinusitis.
400 mg orally once daily with or without food.
None Documented
None Documented
12.5 hours (range 10-16 hours), supporting once-daily dosing.
Terminal half-life: 12 hours; allows once-daily dosing
Renal excretion of unchanged drug accounts for approximately 61% of the administered dose; fecal elimination accounts for about 35%, with a minor biliary component.
Renal: 70% unchanged; biliary/fecal: 20%; metabolized: 10%
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic